On January 25, 2019 NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company (the "Company") focused on significantly improving treatment outcomes for patients with cancer, reported that it has withdrawn the proposed underwritten offering of American Depositary Shares ("ADSs") (Press release, Nucana BioPharmaceuticals, JAN 25, 2019, View Source [SID1234532903]). The Company believes it is not in the best interest of its shareholders to raise equity capital in the current market environment. The Company remains well capitalized with a cash position of approximately £77 million as of December 31, 2018 to fund its key programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!